Immunic, inc. (VTL)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating expenses:
Research and development

6,434

6,026

7,102

6,029

3,355

-4,129

1,410

2,157

10,157

10,190

9,689

9,834

9,628

8,862

7,469

6,858

6,857

6,829

9,646

11,545

11,753

10,891

10,244

9,125

9,219

7,654

6,163

4,538

3,432

General and administrative

2,580

2,160

2,075

8,978

1,307

-2,841

395

513

4,335

4,590

2,950

2,715

3,059

2,963

2,770

2,688

2,799

3,061

2,689

3,533

3,064

3,127

2,566

2,513

2,657

2,594

3,002

2,525

1,494

Severance costs

-

-

-

-

-

-

-

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of Long-Lived Assets Held-for-use

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

9,014

8,186

9,177

15,007

4,662

-6,970

1,805

2,670

14,492

14,780

12,639

12,549

12,687

11,825

10,239

9,546

9,656

9,890

12,335

15,078

14,817

14,018

12,810

11,638

11,876

10,248

9,165

7,063

4,926

Loss from operations

-9,014

-8,186

-9,177

-15,007

-4,662

6,970

-1,805

-2,670

-14,492

-14,780

-12,639

-12,549

-12,687

-11,825

-10,239

-9,546

-9,656

-9,890

-12,335

-15,078

-14,817

-14,018

-12,810

-11,638

-11,876

-10,248

-9,165

-7,063

-4,926

Other income (expense):
Interest income

24

15

58

34

0

-

0

0

170

197

187

169

97

70

79

75

60

23

13

12

10

8

5

4

2

1

1

1

2

Other income, net

503

480

904

259

349

514

8

0

-66

-5

-29

-27

-12

21

-18

3

7

8

22

-40

49

56

7

-5

-2

-

-5

-4

-

Revaluation of future purchase rights liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,472

1,128

14

2,192

922

-4,434

Total other income

527

495

962

293

349

343

8

0

104

192

158

142

85

91

61

78

67

31

35

-28

59

64

12

1,471

1,128

9

2,188

919

-4,432

Net loss

-8,487

-7,691

-8,215

-14,714

-4,313

7,313

-1,797

-2,670

-14,388

-14,588

-12,481

-12,407

-12,602

-11,734

-10,178

-9,468

-9,589

-9,859

-12,300

-15,106

-14,758

-13,954

-12,798

-10,167

-10,748

-8,143

-6,977

-7,267

-10,331

Net loss before cumulative effect of change in accounting principle

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,358

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,144

-9,358

Amortization of deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4,722

22

43

10

8

3

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,362

3,048

2,171

2,047

1,115

970

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,954

-12,798

-16,251

-13,818

-

-9,034

-

-

Net loss per share, basic and diluted (in USD per share)

-0.79

2.91

-0.82

-1.52

-5.09

-8.02

-2.12

-3.15

-0.34

-0.33

-0.30

-0.29

-0.39

-0.38

-0.32

-0.30

-0.31

-0.31

-0.51

-0.63

-0.62

22.45

-0.59

-0.91

-24.49

-22.11

-16.31

-14.33

-22.11

Weighted Average Number of Shares Outstanding, Basic

-

-

-

-

-

-

-

-

42,368

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding, basic and diluted (in shares)

10,749

10,350

10,022

9,669

846

-

846

846

-

42,376

42,207

42,207

32,645

32,094

31,645

31,247

30,563

28,617

24,025

23,996

23,972

24,006

21,759

17,888

564

560

553

507

467